SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-044239
Filing Date
2023-02-22
Accepted
2023-02-22 09:07:09
Documents
12
Period of Report
2023-02-22
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d470958d8k.htm   iXBRL 8-K 24777
  Complete submission text file 0001193125-23-044239.txt   150180

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cadl-20230222.xsd EX-101.SCH 2853
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20230222_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20230222_pre.xml EX-101.PRE 11709
6 EXTRACTED XBRL INSTANCE DOCUMENT d470958d8k_htm.xml XML 3466
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 23650666
SIC: 2836 Biological Products, (No Diagnostic Substances)